RECEIVED
CENTRAL FAX CENTER
JAN 17 2007

CURRENT LISTING OF CLAIMS

1. (currently amended) A compound according to formula I



I

wherein

R^1 is selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-7} cycloalkyl, C_{1-3} alkoxy-C_{1-3} alkyl, phenyl and benzyl, wherein,

said phenyl and said benzyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6}alkoxy,

C_{1-6} haloalkoxy, C_{1-6} alkylthio, nitro, halogen and cyano;

R^2 is phenyl ~~or pyridyl~~ optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, and $CONR^6R^7$;

R^3 is substituted C_{1-6} alkyl, substituted C_{1-3} alkoxy-C_{1-3} alkyl, substituted C_{3-6} alkenyl, C_{3-7} cycloalkyl, optionally substituted C_{1-} alkoxy, $(CH_2)_nR^5$, $CH(OH)R^5$, $-(CH_2)_n-O-(CH_2)_pR^5$, NR^6R^7, $C(=Y)Z$[[,]] or $-X(C=Y)Z$ ~~or IIa-c~~;



(IIa) (IIb) (IIc)

wherein,

said alkyl, said C_{1-3} alkoxy-C_{1-3} alkyl and said alkenyl are substituted by -OH, $-NR^6R^7$, $-C(=Y)Z$, $-X(C=Y)Z$, CN, $-S(O)_q-C_{1-6}$ alkyl; $-SO_2NR^6R^7$, $-SO_2NHNH_2$, or $-NR^6SO_2-C_{1-6}$ alkyl;

said alkoxy is optionally substituted by -OH, $-NR^6R^7$, $-C(=Y)Z$, $-X(C=Y)Z$, $-S(O)_q-C_{1-6}$ alkyl; $-SO_2NR^6R^7$ or $-SO_2NHNH_2$;

~~R^{12} is hydrogen, C_{1-6}alkyl or $-C(=Y)Z$;~~

PAGE 3/11 * RCVD AT 1/17/2007 4:04:30 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-3/20 * DNIS:2738300 * CSID:650 855 5322 * DURATION (mm-ss):03-12

R^3 is a phenyl ~~or a heteroaryl ring according to formula IIIa-IIIh said phenyl and said heteroaryl ring~~ optionally substituted with halo, $-OR^6$, $-NR^6R^7$, $-C(=O)Z$, $-X(C=O)Z$;


(IIIa)


(IIIb)


(IIIc)


(IIId)


(IIIe)


(IIIf)


(IIIg)


(IIIh)

wherein

~~X^1 is selected from the group consisting of $-R^{10}C=CR^{10a}-$, $-O-$, $-S-$, $-NR^6-$ and $-CHR^6-$;~~

~~X^2 is selected from the group consisting of $-R^{10}C=CR^{10a}-$, $-O-$, $-S-$, and $-CHR^6-$;~~

~~X^3 is selected from the group consisting of hydrogen, hydroxyl and thiol;~~

~~R^{10} and R^{10a} are independently are selected from the group consisting of hydrogen or C_{1-6} alkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, C_{1-6}alkoxy, thiol, C_{1-6}alkylthio, C_{1-6} alkylsulfinyl, C_{1-6}alkylsulfonyl, halogen, amino, C_{1-6}alkylamino, C_{1-3}dialkylamino, amino-C_{1-3}alkyl, C_{1-3}alkylamino-C_{1-3}alkyl, and C_{1-3}dialkylamino-C_{1-3}alkyl;~~

~~said phenyl and said heteroaryl ring~~ is ~~optionally substituted with halo, $-OR^6$, $-NR^6R^7$, $-C(=O)Z$, $-X(C=O)Z$~~

R^4 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl~~[[,]] C_{3-7}cycloalkyl, C_{1-3}alkoxy-C_{1-3}alkyl, $(CH_2)_aR^{11}$ or $(CH_2)_o$-O-$(CH_2)_pR^{11}$~~;

wherein,

said alkyl, said alkenyl~~[[,]]~~ and said alkynyl ~~and said cycloalkyl~~ are optionally substituted by $-OH$, $-OR^6$, $-NR^8R^9$, $-C(=Y)Z$, $-X(C=Y)Z$, $-S(O)_q-C_{1-6}$alkyl, $-SO_2NR^6R^7$ or $-SO_2NHNH_2$;

PAGE 4/11 * RCVD AT 1/17/2007 4:04:30 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-3/20 * DNIS:2738300 * CSID:650 855 5322 * DURATION (mm-ss):03-12

~~R^{11} is a phenyl or a heteroaryl ring selected from the group consisting of pyridinyl, pyrimidinyl pyrazinyl, pyrrole, imidazole, pyrazole and thiophene, said heteroaryl ring and said phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl and C_{1-3} alkoxy; or R^{11} is $N[(CH_2)_2]_2W$ wherein W is selected from the group consisting of NR^6, $(CH_2)_{n-3}$, $N(C=O)Z$, $CHOR^6$, CHR^6, $CHNHC(=O)Z$ and $CHNR^6R^7$;~~

n, o, p and q are as defined below ~~and s is 0 or 1~~;

R^6, R^7, R^8 and R^9 ~~(i)~~ taken independently are selected from the group consisting of hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-3} alkoxy-C_{1-3} alkyl C_{1-3} alkylamino-C_{1-3} alkyl and C_{1-3} dialkylamino-C_{1-3} alkyl ~~or (ii) when both R^6 and R^7 are attached to the same nitrogen atom they may be taken together, along with the nitrogen, to form a pyrrolidine, piperidine, piperazine or morpholine~~;

X, and Y are independently O or NR^6;

Z is hydrogen, hydroxyl, C_{1-6} alkoxy, NR^6R^{13}, C_{1-6} alkyl, C_{1-3} alkoxy-C_{1-3} alkyl wherein R^{13} is R^7 or phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl and C_{1-3} alkoxy;

n is 0 to 3;

o and p are independently 0 to 4 and $o + p \leq 5$;

q is 0 to 2; and,

~~k, r1 and r2 are independently 0 to 4, and $5 \geq (r1 + r2) \geq 2$; and,~~

acid addition salts, hydrates and solvates thereof; ~~with the proviso that when R^4 is $-(CH_2)_nR^{11}$, n is 1 and R^{11} is substituted phenyl, R^3 is other than unsubstituted phenyl.~~

2. (currently amended) A compound according to claim 1 wherein:

R^1 is selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-7} cycloalkyl, C_{1-3} alkoxy-C_{1-3} alkyl and optionally-substituted phenyl; and

~~R^3 is optionally substituted phenyl; and,~~

R^4 is C_{1-6} alkyl[[,]] ~~C_{3-7} cycloalkyl, $(CH_2)_nR^{11}$ or $-(CH_2)_o-O-(CH_2)_pR^{11}$; wherein,~~

said alkyl ~~and said cycloalkyl are~~ optionally substituted by-OH, $-OR^6$, $-NR^8R^9$, $-C(=Y)Z$ or $-X(C=Y)Z$[[,]].

~~R^{11} is a phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl and C_{1-3} alkoxy.~~

PAGE 5/11 * RCVD AT 1/17/2007 4:04:30 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-3/20 * DNIS:2738300 * CSID:650 855 5322 * DURATION (mm-ss):03-12

3. (currently amended) A compound according to claim 2 wherein R^3 is substituted C_{1-6} alkyl[[,]] ~~IIa-c or $-(CH_2)_nR^5$ wherein R^5 is IIa-IIh~~.

4. (original) A compound according to claim 2 wherein R^3 is $-(CH_2)_nNR^6R^7$, $-(CH_2)_nC(=O)Z$ or $-(CH_2)_nXC(=O)Z$.

5 - 16. (canceled)

17. (currently amended) A pharmaceutical composition comprising a therapeutically effective quantity of a compound of formula I



I

wherein

R^1 is selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} alkenyl, C_{3-6} alkynyl, C_{3-7} cycloalkyl, C_{1-3} alkoxy-C_{1-3} alkyl, phenyl and benzyl, wherein, said phenyl and said benzyl optionally substituted with one to three substituents independently selected from the group consisting of C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} alkoxy, C_{1-6} haloalkoxy, C_{1-6} alkylthio, nitro, halogen and cyano;

R^2 is phenyl ~~or pyridyl~~ optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, and $CONR^6R^7$;

R^3 is substituted C_{1-6} alkyl, substituted C_{1-3} alkoxy-C_{1-3} alkyl, substituted C_{3-6} alkenyl, C_{3-7} cycloalkyl, optionally substituted C_{1-6} alkoxy, $-(CH_2)_nR^5$, $-CH(OH)R^5$, $-(CH_2)_o-O-(CH_2)_pR^5$, $-NR^6R^7$, $-C(=Y)Z$, or $-X(C=Y)Z$ ~~or IIa-e~~;



(IIa) (IIb) (IIc)

wherein,

PAGE 6/11 * RCVD AT 1/17/2007 4:04:30 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-3/20 * DNIS:2738300 * CSID:650 855 5322 * DURATION (mm-ss):03-12

said alkyl, said C_{1-3} alkoxy-C_{1-3} alkyl and said alkenyl are substituted by -OH, $-NR^6R^7$, -C(=Y)Z, -X(C=Y)Z, CN, $-S(O)_q$-C_{1-6}alkyl, $-SO_2NR^6R^7$, $-SO_2NHNH_2$, or $-NR^6SO_2$-C_{1-6}alkyl;

said alkoxy is optionally substituted by -OH, $-NR^6R^7$, -C(=Y)Z, -X(C=Y)Z, $-S(O)_q$-C_{1-6} alkyl; $-SO_2NR^6R^7$ or $-SO_2NHNH_2$;

~~R^{12} is hydrogen, C_{1-6}alkyl or -C(=Y)Z;~~

R^5 is a phenyl ~~or a heteroaryl ring according to formula IIIa-IIIh~~ optionally substituted with halo, $-OR^6$, $-NR^6R^7$, -C(=O)Z, -X(C=O)Z;



(IIIa)



(IIIb)



(IIIc)



(IIId)



(IIIe)



(IIIf)



(IIIg)



(IIIh)

~~wherein~~

~~X^1 is selected from the group consisting of $R^{10}C=CR^{10a}$, -O-, -S-, $-NR^6$- and $-CHR^6$;~~

~~X^2 is selected from the group consisting of $R^{10}C=CR^{10a}$, -O-, -S-, and $-CHR^6$-;~~

~~X^3 is selected from the group consisting of hydrogen, hydroxyl and thiol;~~

~~R^{10} and R^{10a} are independently are selected from the group consisting of hydrogen or C_{1-6} alkyl optionally substituted with one or two substituents independently selected from the group consisting of hydroxy, C_{1-6}alkoxy, thiol, C_{1-6}alkylthio, C_{1-6} alkylsulfinyl, C_{1-6}alkylsulfonyl, halogen, amino, C_{1-6}alkylamine, C_{1-3}dialkylamino, amino-C_{1-3}alkyl, C_{1-3}alkylamino-C_{1-3}alkyl, and C_{1-3}dialkylamino-C_{1-3}alkyl;~~

~~said phenyl and said heteroaryl ring optionally substituted with halo, OR^6, $-NR^6R^7$, -C(=O)Z, -X(C=O)Z;~~

PAGE 7/11 * RCVD AT 1/17/2007 4:04:30 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-3/20 * DNIS:2738300 * CSID:650 855 5322 * DURATION (mm-ss):03-12

R^4 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, ~~C_{3-7}cycloalkyl, C_{1-3}alkoxy-C_{1-3}alkyl, $(CH_2)_nR^{11}$ or $(CH_2)_o$-O-$(CH_2)_pR^{11}$~~; wherein,

said alkyl, said alkenyl[[,]] and said alkynyl ~~and said cycloalkyl~~ are optionally substituted by -OH, $-OR^6$, $-NR^8R^9$, -C(=Y)Z, -X(C=Y)Z, $-S(O)_q$-C_{1-6}alkyl, $-SO_2NR^6R^7$ or $-SO_2NHNH_2$;

~~R^{11} is a phenyl or a heteroaryl ring selected from the group consisting of pyridinyl, pyrimidinyl pyrazinyl, pyrrole, imidazole, pyrazole and thiophene, said heteroaryl ring and said phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3} alkyl, C_{1-3} haloalkyl and C_{1-3} alkoxy; or R^{11} is $N[(CH_2)_2]_2W$ wherein W is selected from the group consisting of NR^6, $(CH_2)_n$, N(C=O)Z, $CHOR^6$, CHR^6-CHNHC(=O)Z and $CHNR^6R^7$;~~

n, o, p and q are as defined below ~~and s is 0 or 1~~;

R^6, R^7, R^8 and R^9 ~~(i)~~ taken independently are hydrogen, C_{1-6} alkyl, C_{1-6} hydroxyalkyl, C_{1-3} alkoxy-C_{1-3} alkyl C_{1-3} alkylamino-C_{1-3}alkyl or C_{1-3} dialkylamino-C_{1-3}alkyl ~~or (ii) when both R^6 and R^7 are attached to the same nitrogen atom they may be taken together, along with the nitrogen, to form a pyrrolidine, piperidine, piperazine or morpholine~~;

X, and Y are independently O or NR^6;

Z is hydrogen, hydroxyl, C_{1-6}alkoxy, NR^6R^{13}, C_{1-6}alkyl, C_{1-3}alkoxy-C_{1-3}alkyl wherein R^{13} is R^7 or phenyl optionally substituted with one to three groups independently selected from the group consisting of halogen, cyano, C_{1-3}alkyl, C_{1-3}haloalkyl and C_{1-3}alkoxy;

n is 0 to 3;

o and p are independently 0 to 4 and $o + p \leq 5$;

q is 0 to 2;

~~k, r1 and r2 are independently 0 to 4, and $5 \geq (r1 + r2) \geq 2$; and,~~

acid addition salts, hydrates and acid addition salts, hydrates and solvates thereof, ~~with the proviso that when R^4 is $(CH_2)_nR^{11}$, n is 1 and R^{11} is substituted phenyl, R^2 is other than unsubstituted phenyl,~~ in admixture with at least one pharmaceutically acceptable carrier or diluent sufficient upon administration in a single or multiple dose regimen for treating diseases mediated by human immunodeficiency virus or for inhibiting HIV.

* * * * * * * * *

PAGE 8/11 * RCVD AT 1/17/2007 4:04:30 PM [Eastern Standard Time] * SVR:USPTO-EFXRF-3/20 * DNIS:2738300 * CSID:650 855 5322 * DURATION (mm-ss):03-12